Palatin has a research program in DR, and more specifically, in diabetic macular edema (DME), a complication of DR that ...

The agreement with Palatin follows a $1bn deal with Re-Vana earlier this year as Boehringer targets the ophthalmology market.

Ozempic may have serious side effects, including thyroid cancer and problems with the pancreas, gallbladder, kidneys, and ...

Fully autonomous screening for diabetic retinopathy is coming to pharmacies and other locations through a strategic ...

Comprehensive eye exams are vital for detecting early signs of systemic diseases like diabetes, hypertension, and high ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

In an era where chronic diseases are reshaping global health priorities, the diabetic retinopathy market stands out as a ...

Eye floaters, those drifting spots in your vision, are often harmless but can signal hypertension or diabetes. High blood ...

The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor ...

Microaneurysm (MA) turnover increases with the progression of nonproliferative diabetic retinopathy (NPDR) and is correlated with presence of intraretinal microvascular abnormalities (IRMAs), ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...